Valuation: Neuronetics, Inc.

Capitalization 91.77M 78.69M 73.59M 68.73M 128M 8.24B 139M 863M 333M 3.9B 344M 337M 14.2B P/E ratio 2025 *
-2.26x
P/E ratio 2026 * -2.91x
Enterprise value 91.77M 78.69M 73.59M 68.73M 128M 8.24B 139M 863M 333M 3.9B 344M 337M 14.2B EV / Sales 2025 *
0.62x
EV / Sales 2026 * 0.56x
Free-Float
48.49%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+8.21%
1 week-2.68%
Current month-2.68%
1 month-49.48%
3 months-56.19%
6 months-62.63%
Current year-9.94%
More quotes
1 week 1.28
Extreme 1.28
1.53
1 month 1.25
Extreme 1.25
2.93
Current year 1.25
Extreme 1.25
5.92
1 year 1
Extreme 1.001
5.92
3 years 0.52
Extreme 0.52
6.95
5 years 0.52
Extreme 0.52
22.43
10 years 0.52
Extreme 0.52
39.39
More quotes
Manager TitleAgeSince
Chief Executive Officer 66 2020-07-13
Director of Finance/CFO 53 2025-07-14
Chief Operating Officer 68 2025-06-18
Director TitleAgeSince
Director/Board Member 66 2017-06-30
Director/Board Member 64 2019-09-30
Director/Board Member 66 2020-07-13
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+8.21%-2.68%+23.40%-76.61% 91.77M
-0.90%-2.64%+8.77%+3.24% 218B
-0.19%-0.85%+3.40%+110.82% 202B
-0.58%+0.15%-3.86%-15.24% 161B
-0.86%-3.80%+7.57%+115.15% 146B
+0.76%+0.78%-17.43%-17.24% 55.09B
+2.14%-1.03%+15.61%+16.15% 48.73B
-0.63%-3.37%+5.79%-2.87% 42.25B
-1.28%+3.16%-0.59% - 38.08B
+0.03%-1.69%+2.31%+14.66% 36.65B
Average +0.75%-1.31%+4.50%+16.45% 94.84B
Weighted average by Cap. -0.22%-1.25%+3.36%+41.41%
See all sector performances

Financials

2025 *2026 *
Net sales 148M 127M 119M 111M 207M 13.3B 224M 1.39B 538M 6.29B 556M 544M 22.92B 164M 141M 132M 123M 229M 14.74B 248M 1.54B 596M 6.97B 616M 603M 25.4B
Net income -39.29M -33.69M -31.51M -29.43M -54.8M -3.53B -59.36M -370M -143M -1.67B -147M -144M -6.08B -32.4M -27.79M -25.99M -24.27M -45.19M -2.91B -48.95M -305M -118M -1.38B -122M -119M -5.01B
Net Debt - -
More financial data * Estimated data
Logo Neuronetics, Inc.
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Employees
716
More about the company
Date Price Change Volume
25-12-04 1.450 $ +8.21% 856,365
25-12-03 1.340 $ +1.52% 912,152
25-12-02 1.320 $ -7.04% 1,586,915
25-12-01 1.420 $ -4.70% 1,569,042
25-11-28 1.490 $ +7.19% 1,063,334

Delayed Quote Nasdaq, December 04, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.340USD
Average target price
6.500USD
Spread / Average Target
+385.07%
Consensus

Quarterly revenue - Rate of surprise